Patents by Inventor Steven Shak

Steven Shak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190055317
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Application
    Filed: October 29, 2018
    Publication date: February 21, 2019
    Applicant: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • Patent number: 10179936
    Abstract: Algorithm-based molecular assays that involve measurement of expression levels of prognostic and/or predictive genes, or co-expressed genes thereof, from a biological sample obtained from a cancer patient, and analysis of the measured expression levels to provide information concerning the likelihood of recurrence of colorectal cancer and/or the likelihood of a beneficial response to chemotherapy for the patient are provided herein. Methods of analysis of gene expression values of prognostic and/or predictive genes, as well as methods of identifying gene expression-tumor region ratios, tumor-associated stromal surface area, and gene cliques, i.e. genes that co-express with a validated biomarker and thus may be substituted for that biomarker in an assay, are also provided.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: January 15, 2019
    Assignee: Genomic Health, Inc.
    Inventors: Steven Shak, Drew Watson, Xitong Li, Lawrence Lee, Kim Clark-Langone
  • Patent number: 10181008
    Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: January 15, 2019
    Assignee: Genomic Health, Inc.
    Inventors: Steven Shak, George Andrew Watson, Michael R. Crager, Tara Maddala, Margarita Lopatin, Audrey Goddard, Dejan Knezevic, Christer Svedman
  • Patent number: 10160811
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: December 25, 2018
    Assignee: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • Publication number: 20180230548
    Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.
    Type: Application
    Filed: February 15, 2018
    Publication date: August 16, 2018
    Applicant: Genomic Health, Inc.
    Inventors: Melody A. Cobleigh, Steven Shak, Joffre B. Baker, Maureen T. Cronin
  • Patent number: 9944990
    Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: April 17, 2018
    Assignee: GENOMIC HEALTH, INC.
    Inventors: Melody A. Cobleigh, Steven Shak, Joffre B. Baker, Maureen T. Cronin
  • Publication number: 20180051348
    Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
    Type: Application
    Filed: August 11, 2017
    Publication date: February 22, 2018
    Applicants: Genomic Health, Inc., NSABP Foundation, Inc.
    Inventors: Joffre B. BAKER, John L. BRYANT, Soonmyung PAIK, Steven SHAK
  • Publication number: 20170121780
    Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
    Type: Application
    Filed: December 5, 2016
    Publication date: May 4, 2017
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Wayne COWENS, Steven SHAK, Audrey GODDARD, Dejan KNEZEVIC, Joffre BAKER, Michael C. KIEFER, Tara MADDALA, Frederick L. BAEHNER
  • Patent number: 9605318
    Abstract: The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: March 28, 2017
    Assignee: Genomic Health, Inc.
    Inventors: Joffre B. Baker, Steven Shak, Luca Gianni
  • Patent number: 9551034
    Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: January 24, 2017
    Assignee: Genomic Health, Inc.
    Inventors: Wayne Cowens, Steven Shak, Audrey Goddard, Dejan Knezevic, Joffre Baker, Michael C. Kiefer, Tara Maddala, Frederick L. Baehner
  • Publication number: 20160097105
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: October 20, 2015
    Publication date: April 7, 2016
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
  • Publication number: 20160048632
    Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence.
    Type: Application
    Filed: May 29, 2014
    Publication date: February 18, 2016
    Applicant: Genomic Health, Inc.
    Inventors: Steven SHAK, George Andrew WATSON, Michael R. CRAGER, Tara MADDALA, Margarita LOPATIN, Audrey GODDARD, Dejan KNEZEVIC, Christer SVEDMAN
  • Publication number: 20150079591
    Abstract: The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i) Recurrence Score, (ii) ESRI Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; and (v) the expression level of the RNA transcript of at least one of MYBL2 and SCUBE2, or the corresponding expression product. The invention further comprises a molecular assay-based algorithm to calculate the likelihood that the patient will have a beneficial response to chemotherapy based on the risk score.
    Type: Application
    Filed: September 18, 2014
    Publication date: March 19, 2015
    Inventors: Joffre B. BAKER, John L. BRYANT, Soonmyung PAIK, Steven SHAK
  • Patent number: 8868352
    Abstract: The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i) Recurrence Score, (ii) ESRI Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; and (v) the expression level of the RNA transcript of at least one of MYBL2 and SCUBE2, or the corresponding expression product. The invention further comprises a molecular assay-based algorithm to calculate the likelihood that the patient will have a beneficial response to chemotherapy based on the risk score.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: October 21, 2014
    Assignees: Genomic Health, Inc., NSABP Foundation, Inc.
    Inventors: Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak
  • Publication number: 20140303002
    Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.
    Type: Application
    Filed: March 21, 2014
    Publication date: October 9, 2014
    Applicant: Genomic Health, Inc.
    Inventors: Steven Shak, Mark Lee, William F. Novotny, Tara Maddala, Michael R. Crager, Diana Cherbavaz, Robert J. Pelham, Carl L. Millward, Dejan Knezevic
  • Publication number: 20140287421
    Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.
    Type: Application
    Filed: April 21, 2014
    Publication date: September 25, 2014
    Applicant: Genomic Health, Inc.
    Inventors: Melody A. Cobleigh, Steven Shak, Joffre B. Baker, Maureen T. Cronin
  • Publication number: 20140079692
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Application
    Filed: November 6, 2013
    Publication date: March 20, 2014
    Applicant: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • Publication number: 20130149299
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Application
    Filed: March 8, 2012
    Publication date: June 13, 2013
    Inventors: Sharon A. Baughman, Steven Shak
  • Publication number: 20120270228
    Abstract: The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.
    Type: Application
    Filed: July 5, 2012
    Publication date: October 25, 2012
    Applicants: BRISTOL-MYERS SQUIBB COMPANY, GENOMIC HEALTH, INC.
    Inventors: Joffre B. Baker, Drew Watson, Tara Maddala, Steven Shak, David J. Mauro, Shirin K. Ford
  • Patent number: 8273534
    Abstract: The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: September 25, 2012
    Assignees: Genomic Health, Inc., Bristol-Myers Squibb Company
    Inventors: Joffre B. Baker, Drew Watson, Tara Maddala, Steven Shak, David J. Mauro, Shirin K. Ford